Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRISBANE, CALIF., AUG. 08, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON AUGUST 4, 2025, THE COMPENSATION COMMITTEE OF VERA'S BOARD OF DIRECTORS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 99,000 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 48,200 SHARES OF CLASS A COMMON STOCK TO EIGHT (8) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN). THE COMPENSATION COMMITTEE APPROVED THE AWARDS AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

ON TRACK TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) FOR ACCELERATED APPROVAL OF ATACICEPT TO U.S. FDA IN Q4 2025; POTENTIAL COMMERCIAL LAUNCH IN 2026 ANNOUNCED POSITIVE PRIMARY ENDPOINT RESULTS FROM THE ONGOING ORIGIN PHASE 3 TRIAL INITIATED THE PIONEER TRIAL TO INVESTIGATE ATACICEPT IN A BROADER IGAN PATIENT COHORT AND MULTIPLE AUTOIMMUNE GLOMERULAR DISEASES EXPECTED TO PRESENT FULL PRIMARY ENDPOINT RESULTS FROM THE ORIGIN 3 TRIAL AT A MEDICAL CONGRESS IN Q4 2025 BRISBANE, CALIF., AUG. 05, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY REPORTED ITS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

VERA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

BRISBANE, CALIF. , JULY 10, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT ON JULY 6, 2025, THE COMPENSATION COMMITTEE GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 133,500 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) FOR 73,695 SHARES OF CLASS A COMMON STOCK TO FIFTEEN (15) NEW EMPLOYEES UNDER THE INDUCEMENT PLAN. THE COMPENSATION COMMITTEE APPROVED THE AWARDS AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

VERA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BRISBANE, CALIF., JUNE 09, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT ON JUNE 3, 2025, THE COMPENSATION COMMITTEE GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 124,000 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) FOR 65,925 SHARES OF CLASS A COMMON STOCK TO SEVENTEEN (17) NEW EMPLOYEES UNDER THE INDUCEMENT PLAN. THE COMPENSATION COMMITTEE APPROVED THE AWARDS AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

BRISBANE, CALIF., JUNE 04, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, WHICH IS TAKING PLACE IN MIAMI BEACH, FL FROM JUNE 9  11, 2025. THE MANAGEMENT TEAM WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

VERA THERAPEUTICS TO PARTICIPATE IN THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

BRISBANE, CALIF., JUNE 03, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A NEW CREDIT FACILITY PROVIDING FOR UP TO $500 MILLION OF TERM LOANS WITH ITS CURRENT PARTNER OXFORD FINANCE LLC (OXFORD). THE NEW CREDIT FACILITY WILL REPLACE VERA'S EXISTING $50 MILLION CREDIT FACILITY. THE INITIAL FUNDING OF THE NEW CREDIT FACILITY WILL BE IN A PRINCIPAL AMOUNT OF $75 MILLION AND IS EXPECTED TO OCCUR ON JUNE 4, 2025.

VERA THERAPEUTICS ANNOUNCES REFINANCING OF EXISTING OXFORD DEBT FACILITY,PROVIDING UP TO $500 MILLION OF TERM LOANS

BRISBANE, CALIF., JUNE 02, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT THE PRIMARY ENDPOINT WAS MET IN THE ORIGIN PHASE 3 TRIAL OF ATACICEPT FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS.

VERA THERAPEUTICS ANNOUNCES ATACICEPT ACHIEVED 46% PROTEINURIA REDUCTION IN ORIGIN PHASE 3 TRIAL IN ADULTS WITH IGA NEPHROPATHY

BRISBANE, CALIF., MAY 09, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT ON MAY 5, 2025, THE COMPENSATION COMMITTEE GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 111,750 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) FOR 62,575 SHARES OF CLASS A COMMON STOCK TO ELEVEN (11) NEW EMPLOYEES UNDER THE INDUCEMENT PLAN. THE COMPENSATION COMMITTEE APPROVED THE AWARDS AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ON TRACK TO ANNOUNCE THE PRIMARY ENDPOINT RESULTS FROM THE ATACICEPT PIVOTAL PHASE 3 ORIGIN TRIAL IN IGA NEPHROPATHY (IGAN) IN 2Q 2025; PLANNING FOR BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION FOR ATACICEPT ACCELERATED APPROVAL TO THE U.S. FDA IN 4Q 2025 EXPANDED ATACICEPT DEVELOPMENT PROGRAM ACROSS MULTIPLE AUTOIMMUNE KIDNEY DISEASES IS UNDERWAY BRISBANE, CALIF., MAY 06, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY REPORTED ITS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

VERA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

BRISBANE, CALIF., APRIL 09, 2025 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT ON APRIL 3, 2025, THE COMPENSATION COMMITTEE GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 211,250 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) FOR 105,125 SHARES OF CLASS A COMMON STOCK TO SIXTEEN (16) NEW EMPLOYEES UNDER THE INDUCEMENT PLAN. THE COMPENSATION COMMITTEE APPROVED THE AWARDS AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Vera Therapeutics, Inc.

VERA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vera Therapeutics, Inc.

VERA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VERA